EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Fatty acid Sources: 6

Algal oil (DHA and EPA)

Also called: algae oil, algal DHA, microalgae oil, Schizochytrium oil

An oil from microalgae, such as Schizochytrium species grown by fermentation, that supplies the omega-3 fatty acid DHA and in some products EPA. NCCIH describes algal oils as a vegetarian source of DHA. General omega-3 information is in the omega-3 fatty acids entry.

Category
Fatty acid
Forms
Algal oil, DHA-rich or DHA plus EPA; forms on FDA's NDI list include ethyl ester, re-esterified triglyceride (r-TG) and monoacylglycerol (MAG) oils
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. A 2012 meta-analysis identified 11 RCTs (485 healthy participants) of algal-oil DHA supplementation and blood lipids; the median dose was 1.68 g DHA per day. [3]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

2 topics studied2 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Algal oil (DHA and EPA) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Algal oil (DHA and EPA), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Blood lipids in people without coronary heart diseaseBA 2012 meta-analysis (11 RCTs, 485 participants) found algal-oil DHA lowered triglycerides (-0.20 mmol/L) and raised HDL (+0.07 mmol/L) and LDL cholesterol (+0.23 mmol/L). [3]
Reading and behavior in underperforming schoolchildrenCAn RCT in healthy underperforming readers aged 7-9 (362 met criteria; 600 mg/day algal DHA) found no effect on reading overall, benefit in a pre-planned subgroup of the poorest readers, and fewer parent-rated behavior problems. [4]

Main constituents: Docosahexaenoic acid (DHA); some algal oils also contain eicosapentaenoic acid (EPA) [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Median dose in the 2012 lipid meta-analysis: 1.68 g algal DHA per day. [3]
  • DOLAB trial: 600 mg/day DHA from algal oil versus corn/soybean oil placebo. [4]

Upper limits

  • EFSA (2026) could not establish a UL for supplemental DHA alone and retained a safe level of intake of 1 g/day for all population groups, including pregnant and lactating women; it applies to DHA from sources containing DHA alone or mostly DHA (EPA/DHA ratio below 0.3), including algal oils. [5]
Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    EFSA (2026): the safe level of intake of 1 g/day for supplemental DHA alone applies to all population groups, including pregnant and lactating women.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    10 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • EFSA (2026) selected the risk of spontaneous bleeding as the critical effect for supplemental DHA alone, but data were not adequate to characterize a dose-response relationship. [5]
Quality

Identity, quality and standardization

  • ODS: plant-based omega-3 sources from algal oil usually provide around 100-300 mg DHA; some contain EPA as well. [2]
Regulation

Regulatory status

  • US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [6]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Docosahexaenoic acid (DHA); some products also eicosapentaenoic acid (EPA) Fatty acids and lipids (omega-3 long-chain polyunsaturated fatty acids) [P6]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 10 entries naming a DHA or DHA-plus-EPA oil described as algal or algae oil or as derived from Schizochytrium (earliest NDI 19 submitted 1997-12-22; most recent NDI 1379 submitted 2025-01-02). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of algal oil was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P2]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of algal oil (checked 2026-10-30). [P3]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • ODS: according to a small study, the bioavailability of DHA from algal oil is equivalent to that from cooked salmon. [P5]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • EFSA (2026): the safe level of intake of 1 g/day for supplemental DHA alone applies to all population groups, including pregnant and lactating women. [P7]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications (last update 2026-07-23; checked 2026-10-30), 2026-07-23. monographs.iarc.who.int
  3. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, retrieved 2026-10-30), 2026-10-30. ecfr.gov
  5. NIH Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals (no printed update date; page last modified 2026-10-24 per page metadata), 2026-10-24. ods.od.nih.gov
  6. NCCIH. Omega-3 Supplements: What You Need To Know (Last Updated: November 2024), 2024-11. nccih.nih.gov
  7. EFSA NDA Panel. Scientific Opinion on the tolerable upper intake level for supplemental docosahexaenoic acid. EFSA J 2026;24(1):e9858 (PMID 41542352), 2026-01-14. pubmed.ncbi.nlm.nih.gov
Sources

Sources

  1. NCCIH. Omega-3 Supplements: What You Need To Know (Last Updated: November 2024), 2024-11. nccih.nih.gov
  2. NIH Office of Dietary Supplements. Omega-3 Fatty Acids: Fact Sheet for Health Professionals (no printed update date; page last modified 2026-10-24 per page metadata), 2026-10-24. ods.od.nih.gov
  3. Bernstein AM, Ding EL, Willett WC, Rimm EB. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr 2012;142(1):99-104 (PMID 22113870), 2012-01. pubmed.ncbi.nlm.nih.gov
  4. Richardson AJ, et al. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study). PLoS One 2012;7(9):e43909 (PMID 22970149), 2012. pubmed.ncbi.nlm.nih.gov
  5. EFSA NDA Panel. Scientific Opinion on the tolerable upper intake level for supplemental docosahexaenoic acid. EFSA J 2026;24(1):e9858 (PMID 41542352), 2026-01-14. pubmed.ncbi.nlm.nih.gov
  6. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in fatty acid: Arachidonic acid · Argan oil · Conjugated linoleic acid (CLA) · Evening primrose oil · GLA oils (borage and blackcurrant seed oil) · Krill oil · Linoleic acid · MCT oil (medium-chain triglycerides) · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.